Clinical Trials Logo

Hematologic Neoplasms clinical trials

View clinical trials related to Hematologic Neoplasms.

Filter by:

NCT ID: NCT06049667 Recruiting - Clinical trials for Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Start date: August 7, 2023
Phase: Phase 1
Study type: Interventional

NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.

NCT ID: NCT06043011 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

RUBIN
Start date: September 27, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.

NCT ID: NCT06041815 Recruiting - Clinical trials for Hematological Malignancies

Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies

Start date: September 3, 2023
Phase:
Study type: Observational

The purpose of this prospective and observational study is to evaluate the correlation between gut microbiota and clinical response to CAR-T treatment for hematological malignancies

NCT ID: NCT06037018 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Start date: August 7, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell non-Hodgkin lymphoma and B-cell lymphocytic leukemia.

NCT ID: NCT06034275 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Start date: September 13, 2023
Phase: Phase 1
Study type: Interventional

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

NCT ID: NCT06028828 Recruiting - Clinical trials for Hematologic Malignancies

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

ADAPT
Start date: September 11, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.

NCT ID: NCT06018506 Recruiting - Clinical trials for Hematologic Malignancy

A Phase I Study of BR108 in Hematological Malignancies

Start date: March 27, 2023
Phase: Phase 1
Study type: Interventional

A Phase I study of BR108 in hematological malignancies

NCT ID: NCT06010017 Recruiting - Clinical trials for Hematopoietic Malignancy

Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation

STEPP
Start date: February 20, 2024
Phase: N/A
Study type: Interventional

The main purpose of this study is to determine if a novel peer support intervention (STEPP) is feasible among patients undergoing hematopoietic stem cell transplantation (HSCT). The name of the intervention used in this research study is STEPP, a peer support intervention comprised of five learning modules on psychoeducation and supportive psychotherapy strategies, tailored to the unique needs of patients undergoing HSCT.

NCT ID: NCT06001788 Recruiting - Leukemia Clinical Trials

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Start date: February 22, 2024
Phase: Phase 1
Study type: Interventional

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

NCT ID: NCT05968170 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The CliniMACS® device is FDA-approved only for one indication (CD34+ selection). Additional use of this device outside of this indication requires the use of feasibility studies. Children, adolescents and young adults with malignant and non-malignant conditions undergoing hematopoietic stem cell transplants will have stem cells selected using alpha-beta+/CD19+ cell depletion. This is a single arm feasibility study using this processing of peripheral stem cells with alternative donor sources (haploidentical, mismatched, matched unrelated) to determine efficacy as seen by engraftment and graft-versus-host disease (GVHD).